title: Pharmacological management of epilepsy: recent advances and future prospects.
abstract: There is still a need for new antiepileptic drugs (AEDs) as the clinical efficacy, tolerability, toxicity or pharmacokinetic properties of existing AEDs may not be satisfactory. One new AED has recently been approved (rufinamide in 2007) and six others are in late-stage development (phase III and onwards) [brivaracetam, carisbamate, eslicarbazepine, lacosamide, retigabine and stiripentol]. The purpose of this review is to provide updated data on proposed mechanisms of action, efficacy and tolerability on these new AEDs, and to discuss the rationale for their development and possible advantages compared with existing treatment, based on recent publications and MEDLINE searches.Rufinamide, brivaracetam and stiripentol have been given the status of orphan drugs. Rufinamide was approved in Europe in 2007 for the use in Lennox-Gastaut syndrome. Brivaracetam has gained orphan status for development in progressive and symptomatic myoclonic seizures in Europe and the US, respectively. Stiripentol has gained orphan status in children with Dravet's syndrome and pharmaco-resistant epilepsy. All of these drugs demonstrate efficacy as adjunctive therapy in partial seizures. Three of the drugs are derivatives of existing AEDs: brivaracetam is a derivative of levetiracetam with improved affinity for the target molecule; carisbamate is a derivative of felbamate with improved tolerability; and eslicarbazepine is a derivative of carbamazepine with less interaction potential and no auto-induction. Lacosamide, retigabine, rufinamide and stiripentol are new compounds, unrelated to other AEDs.Further investigation and development of new broad-spectrum drugs is important for improved treatment of patients with epilepsy and other neurological and psychiatric disorders.
authors.affiliation: Department of Pharmacy, Faculty of Health Sciences, Oslo University College, Oslo, Norway. cecilie.landmark@hf.hio.no
authors.forename: Cecilie
authors.initials: C
authors.lastname: Johannessen Landmark
authors.forename: Svein I
authors.initials: SI
authors.lastname: Johannessen
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans
chemical_list: D000927:Anticonvulsants
references.citation: Mol Pharmacol. 2000 Sep;58(3):591-600
references.pmid: 10953053
references.citation: Drug Metab Dispos. 2007 Apr;35(4):554-65
references.pmid: 16936066
references.citation: Perspect Medicin Chem. 2008 Feb 14;2:21-39
references.pmid: 19787095
references.citation: Mol Pharmacol. 2008 Jan;73(1):157-69
references.pmid: 17940193
references.citation: Epilepsia. 2008 Oct;49(10):1787-94
references.pmid: 18494790
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6
references.pmid: 15210974
references.citation: Lancet. 2000 Nov 11;356(9242):1638-42
references.pmid: 11089822
references.citation: J Clin Pharmacol. 2002 Feb;42(2):175-82
references.pmid: 11831540
references.citation: Acta Neurol Scand Suppl. 2005;181:68-72
references.pmid: 16238713
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3128-33
references.pmid: 18272489
references.citation: Epilepsia. 2007 Mar;48(3):497-504
references.pmid: 17319919
references.citation: Epilepsy Res. 2008 Mar;79(1):22-30
references.pmid: 18280116
references.citation: Neurology. 2007 Nov 27;69(22):2045-53
references.pmid: 17872363
references.citation: Drug Metab Dispos. 1999 May;27(5):613-22
references.pmid: 10220491
references.citation: Expert Opin Investig Drugs. 2008 Mar;17(3):361-9
references.pmid: 18321235
references.citation: Epilepsy Res. 2006 Jun;69(3):273-94
references.pmid: 16621450
references.citation: Epilepsia. 2008 Jul;49(7):1213-20
references.pmid: 18325020
references.citation: Epilepsia. 2008 Jul;49(7):1123-41
references.pmid: 18503564
references.citation: Neurotherapeutics. 2007 Jan;4(1):149-54
references.pmid: 17199031
references.citation: Epilepsia. 2008 Feb;49(2):343-8
references.pmid: 18028411
references.citation: Epilepsia. 2007 Jul;48(7):1328-38
references.pmid: 17381436
references.citation: Epilepsia. 2006 Nov;47(11):1830-40
references.pmid: 17116022
references.citation: Drug Metab Dispos. 2008 Jan;36(1):36-45
references.pmid: 17908923
references.citation: Med Sci Monit. 2007 Jan;13(1):RA1-7
references.pmid: 17179916
references.citation: Neuropharmacology. 2002 Mar;42(3):346-52
references.pmid: 11897113
references.citation: Neurology. 2008 May 20;70(21):1950-8
references.pmid: 18401024
references.citation: Epilepsia. 2004 Dec;45(12):1498-505
references.pmid: 15571507
references.citation: Nat Med. 2004 Jul;10(7):685-92
references.pmid: 15229516
references.citation: Neurotherapeutics. 2007 Jan;4(1):84-7
references.pmid: 17199019
references.citation: Br J Clin Pharmacol. 2008 Jul;66(1):71-5
references.pmid: 18341673
references.citation: J Med Chem. 1999 Jul 15;42(14):2582-7
references.pmid: 10411478
references.citation: Nat Rev Neurosci. 2004 Jul;5(7):553-64
references.pmid: 15208697
references.citation: Br J Clin Pharmacol. 2003 Jul;56(1):39-45
references.pmid: 12848774
references.citation: Br J Pharmacol. 2002 Jul;136(5):659-72
references.pmid: 12086975
references.citation: Neurochem Int. 2002 Apr;40(5):435-40
references.pmid: 11821151
references.citation: Epilepsia. 2008 Mar;49(3):393-9
references.pmid: 17822432
references.citation: Epilepsia. 1999 Nov;40(11):1618-26
references.pmid: 10565591
references.citation: Neurosci Lett. 2000 Mar 17;282(1-2):73-6
references.pmid: 10713399
references.citation: Neurotherapeutics. 2007 Jan;4(1):106-9
references.pmid: 17199023
references.citation: Neurotherapeutics. 2007 Jan;4(1):123-5
references.pmid: 17199026
references.citation: CNS Drugs. 2008;22(1):27-47
references.pmid: 18072813
references.citation: Epilepsy Res. 2007 Oct;77(1):36-43
references.pmid: 17890056
references.citation: Eur J Pharmacol. 1996 May 15;303(3):163-9
references.pmid: 8813562
references.citation: Epilepsy Res. 2004 Sep-Oct;61(1-3):1-48
references.pmid: 15570674
references.citation: Neurotherapeutics. 2007 Jan;4(1):88-96
references.pmid: 17199020
references.citation: Epilepsia. 2008 Mar;49(3):418-24
references.pmid: 17888078
references.citation: Neurotherapeutics. 2007 Jan;4(1):145-8
references.pmid: 17199030
references.citation: Epilepsia. 2008 Jul;49(7):1239-76
references.pmid: 18397299
references.citation: Epilepsy Res. 2008 May;79(2-3):158-65
references.pmid: 18353614
references.citation: J Med Chem. 2004 Jan 29;47(3):530-49
references.pmid: 14736235
references.citation: J Physiol. 2008 Apr 1;586(7):1791-801
references.pmid: 18238816
references.citation: Epilepsia. 2006 Nov;47(11):1822-9
references.pmid: 17116021
references.citation: Eur J Clin Pharmacol. 2008 Mar;64(3):267-73
references.pmid: 18157705
references.citation: Epilepsy Res. 2007 Jan;73(1):1-52
references.pmid: 17158031
references.citation: Epilepsy Behav. 2008 Jan;12(1):49-53
references.pmid: 18086455
references.citation: Epilepsy Res. 2003 Feb;53(1-2):95-106
references.pmid: 12576171
references.citation: Expert Rev Neurother. 2008 Jun;8(6):929-39
references.pmid: 18505358
references.citation: Br J Pharmacol. 2008 Aug;154(8):1662-71
references.pmid: 18500360
references.citation: Neurotherapeutics. 2007 Jan;4(1):155-62
references.pmid: 17199032
references.citation: Eur J Clin Pharmacol. 2003 Apr;58(12):795-802
references.pmid: 12698305
references.citation: J Child Neurol. 2006 Jun;21(6):496-502
references.pmid: 16948934
references.citation: Expert Opin Investig Drugs. 2006 Jun;15(6):637-47
references.pmid: 16732716
references.citation: Int J Clin Pharmacol Ther. 2008 Mar;46(3):119-30
references.pmid: 18397682
references.citation: Epilepsy Res. 1996 Apr;23(3):211-23
references.pmid: 8739124
references.citation: Epilepsia. 2006 Apr;47(4):704-16
references.pmid: 16650136